The drug combination of lenalidomide (oral capsules) and rituximab (by intravenous injection) has the potential to be an effective treatment for relapsed or refractory follicular and marginal zone lymphoma. The drug combination is being developed for patients that are eligible for rituximab monotherapy or for patients that need an alternative to standard chemotherapy regimens, where rituximab alone would be considered sub-optimal.
Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma
Interventions: Lenalidomide (Revlimid) , Rituximab (MabThera; Rituxan; RG 105)
Indications: Follicular lymphoma , Marginal zone lymphoma (MZL)
Therapeutic Areas: Haematological Cancer and Lymphomas